MMMarilyn Moulds

Marilyn Moulds

*This is an algorithmically generated author record based on publicly available information.

Marilyn Moulds has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • D.F. Stroncek

    Department of Transfusion Medicine , National Institutes of Health , Building 10, Room 1C711, 10 Center Drive-MSC-1184 , Bethesda, MD , India

    2 shared publications
  • L. Castilho

    PhD, Professor and Researcher, Hemocentro-Unicamp, Rua Carlos Chagas 480, Barão Geraldo 13083-878, Campinas, SP, Brazil

    2 shared publications
  • P. Spruell

    2 shared publications
  • S. Murphy

    Musser Blood Center , Philadelphia, PA United States

    2 shared publications
  • S.G. Sandler

    Department of Laboratory Medicine, Georgetown University Hospital, Washington DC 20007, USA

    2 shared publications
  • S.T. Johnson

    Immunology Services , Wisconsin , United States

    2 shared publications

Latest Publications

  • Open Access

    Update on programs for achieving Specialist in Blood Banking certification in the United States: 2023

    by G.M. Meny, M.A. Keller, C. Flickinger

    A person who has achieved the Specialist in Blood Banking (SBB) certification is a medical laboratory scientist who receives advanced training in blood banking and transfusion medicine and has passed an examination given by the American Society for Clinical Pathology. There are several pathways or “eligibility routes” to qualify for the examination to obtain SBB certification, with the most common route involving enrollment in a Commission on Accreditation of Allied Health Education Programs-accredited SBB program. The goal of this study was to compile information about the current accredited SBB programs in the United States and SBB exam statistics for purposes of assessing changes in the programs and detecting trends in SBB exam takers and pass rates. SBB program coordinators were surveyed about qualitative and quantitative aspects of their programs. Current data, changes over time, and nationally available data were tabulated for comparison. This information may be helpful for all medical laboratory scientists interested in considering further studies and certification in blood banking and transfusion medicine.

  • A simple approach to screen rare donors in Brazil

    by C.P. Arnoni, F.R.M. Latini, J.G. Muniz, R.D.M. Person, T.A.P. Vendrame, D. Gazito, L. Castilho

    Providing blood units for patients with an antibody to a high-prevalence antigen or with multiple common antibodies is a constant challenge to the blood banks. Finding a compatible donor requires extensive screening, which incurs a large amount of investment. In this article, we share our experience of organizing a rare donor inventory with limited resources, we include the strategy used for finding rare donors, and we share the difficulties found during the implementation of the approach and the results obtained. Immunohematology 2015;31:20–23.


  • Mass-scale donor red cell genotyping using real-time array technology

    by G.A. Denomme, M.J. Schanen

    Blood centers are in the unique position to evaluate large numbers of blood donations for antigen-negative blood types. The limitations with the use of hemagglutination, however, can be circumvented with red cell genotyping. The reagents used for genotyping are synthesized and can be designed for any of the known blood group antigen single nucleotide polymorphisms that are associated with blood group antigen expression. There is interest in the application of mass-scale red cell genotyping of blood donors to find rare phenotypes and rare combinations of antigens. When performed on donors who are predicted to donate again after testing, integrating the genotype information with existing donor data and demographics provides the blood center with real-time information to identify the common clinically relevant blood group antigens demanded by hospital transfusion services. This review outlines a red cell genotype methodology using TaqMan chemistry and existing algorithms and data handling to gain the full value of mass-scale red cell genotyping of blood donors. Immunohematology 2015;31:69–74.


  • Effects of pH changes of stock normal saline solution on 5 percent red cell suspension

    by G.L. Martin, P.J.M. Caraan, J.J.S. Chua, J.A.L. Crescini, J.M.C. Diokno, C.B.DLr. Javier, M.K.B.O. Reyes, R.Y. Soliven

    The red cell suspension (RCS) is a universally used indicator system to demonstrate antigen and antibody reactions in vitro. Saline solutions that are used in its preparation are preferred to be fresh to avoid changes in pH that may affect the results. Thus, buffered saline such as phosphate-buffered saline (PBS) is the ideal diluent because its pH is maintained for a certain period. However, normal saline solution (NSS) is more commonly used because it is inexpensive and easy to make. pH changes in the saline solutions and the RCSs were monitored for 1 week. Macroscopic examination of changes in degree of redness of RCS was also observed. Red blood cell (RBC) indices of the ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood used in the preparation of the RCS were measured in the performance of an automated complete blood count. Qualitative examination of the crenation of RBCs was done on the prepared blood smears and graded by three registered medical technologists. Percentage crenation was then determined using an improved Neubauer counting chamber. Three trials were performed, and results were averaged. Statistical analysis showed that there were significant differences in the average pH of PBS and NSS and the average pH of RCS-PBS and RCS-NSS over 1 week. RBC indices measured in EDTA-anticoagulated donor blood showed no significant difference. Macroscopic examination of changes in degree of redness of the RCS showed that color darkened over 1 week but only by a small degree. Qualitative and quantitative examination of crenation of RBCs in RCS-PBS and RCS-NSS both showed no significant differences over 1 week. The experimental group (RCS-NSS) continuously showed a higher grade of crenation than the control group (RCS-PBS). Crenation of RBCs still manifests microscopically despite the lack of a significant relationship between the pH of the saline solutions and the degree and percentage of crenation. Crenation, therefore, cannot be attributed to pH alone but occurs as a result of other factors. Immunohematology 2014;30:126–134.


  • Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility

    by H.M. Smith, R.S. Shirey, S.K. Thoman, J.B. Jackson

    More than 50 red blood cell (RBC) alloantibodies are known to cause hemolytic disease of the fetus and newborn (HDFN). Although Rh immune globulin (RhIG) prophylaxis has significantly reduced the incidence of pregnancies complicated by anti-D, the need to detect and monitor maternal alloantibodies capable of causing HDFN is still a concern. The prevalence and specificity of these alloantibodies were determined. In this retrospective study, the prevalence and specificities of unexpected RBC alloantibodies known to cause HDFN in pregnant women at a tertiary-care facility during a 5-year period were compiled and analyzed. Patient selection was carried out by computerized search of patient data based on an obstetric location and the presence or history of RBC antibody between January 1, 2007, and December 31, 2011. The information was organized by ABO and D status of the patient, antibody specificity, and transfusion needs. Of the 8894 obstetric patients identified during the 5-year period, 264 (3.0%) had one or more unexpected RBC antibodies. Of these 264 women, 107 (40.5%), or 1.2 percent overall, had an alloantibody known to cause HDFN, with a total of 15 different alloantibodies identified. The most common alloantibody found was anti-E (n = 33), followed by anti-M (n = 26) and anti-D (n = 20). In pregnancies of D– women, the most common clinically significant antibodies found were anti-D (n = 20), anti-C (n = 11), and anti-E (n = 2). In pregnancies of D+ women, the most common antibodies were anti-E (n = 31), anti-M (n = 25), and anti-K (n = 16). A total of eight pregnancies with alloantibodies required intrauterine transfusions with the specificities of anti-D; anti-D,-C (n = 2); anti-D,-C,-E; anti-D,-C,-K; anti-D,-C,-Jk b ; anti-D,-S; and anti-E,-c. At a large academic tertiary-care center, approximately 1 in 83 obstetric patients had one or more RBC alloantibodies capable of causing HDFN. Anti-E, -M, and -D were the most frequent specificities, respectively. Immunohematology 2013;29:127–130.


  • A novel JK null allele associated with typing discrepancies among African Americans

    by K.L. Billingsley, J.B. Posadas, J.M. Moulds, L.K. Gaur

    The Jk null (Jk-3) phenotype, attributable to null or silenced alleles, has predominantly been found in persons of Polynesian descent. With the increased use of molecular genotyping, many new silencing mutations have been identified in persons of other ethnic backgrounds. To date, only two JK null alleles have been reported in African Americans, JK*01N.04 and JK*01N.05. A comparative study was undertaken to determine whether JK mutations were present in the regional African American population. Results of donor genotyping were compared with previously recorded results of serologic tests, and discrepant results were investigated. Although the two previously identified polymorphisms were not detected in the discrepant samples, a novel allele (191G>A) was identified and was assigned the ISBT number JK*02N.09. This study illustrates a limitation of using single-nucleotide polymorphisms for prediction of blood group antigens. Immunohematology 2013;29:145–148.


  • Seroprevalence of unexpected red blood cell antibodies among pregnant women in Uganda

    by K. Eipl, C. Nakabiito, K. Bwogi, M. Motevalli, A. Roots, L. Blagg, J.B. Jackson

    We conducted a population-based, cross-sectional study among pregnant women in Kampala, Uganda, to determine ABO and D blood types and to determine the percentage who have unexpected red blood cell (RBC) antibodies and their specificities. De-identified blood samples from routine testing of 1001 pregnant women at the Mulago Hospital antenatal clinics in Kampala were typed for ABO and D and screened for the presence of unexpected RBC antibodies with confirmation and subsequent antibody identification. Of the 1001 blood samples tested, 48.9 percent, 26.4 percent, 21.0 percent, and 3.8 percent tested positive for blood groups O, A, B, and AB, respectively. Of these samples, 23 (2.3%) were negative for D, and 55 (5.5%) showed initial reactivity with at least one screening RBC. The RBC antibody screen was repeated on these 55 samples, and antibody identification was performed at the Johns Hopkins Hospital Blood Bank in Baltimore, Maryland. Twenty-one of the 55 samples were confirmed to have evidence of agglutination. Nine of the 21 samples demonstrated the presence of clinically significant RBC antibodies with anti-S being the most common, 8 samples demonstrated the presence of benign or naturally occurring antibodies, and 4 had only inconclusive reactivity. This study revealed a relatively high frequency of D and a low frequency of demonstrable clinically significant alloantibodies that may cause hemolytic disease of the newborn or hemolytic transfusion reactions among pregnant women in Kampala, with anti-S being the most frequent antibody specificity. Immunohematology 2012;28:115–7.


  • Determination of optimal method for antibody identification in a reference laboratory

    by J.R. Haywood, M.K.G. Moulds, B.J. Bryant

    Methods commonly used for antibody identification are hemagglutination (tube), column agglutination (gel), and solid-phase red cell adherence. Our AABB immunohematology reference laboratory (IRL) conducted a study to determine which antibody identification testing method was optimal for detecting all clinically significant antibodies. Patient specimens were sent to our IRL from August 2008 to September 2009. Routine testing was performed by tube method and then by manual gel and manual solid-phase methods. Of the 254 samples tested, 115 showed agreement in antibody identification with all three methods. The tube method identified all but six clinically significant antibodies. The gel method did not identify 59 clinically significant antibodies. Fifty-six clinically significant antibodies were not identified by solid-phase testing. Tube testing identified 27 clinically insignificant antibodies, primarily cold autoantibodies. Gel and solid-phase methodologies identified two and three cold autoantibodies, respectively. Solid-phase testing failed to detect 12 examples of anti-K. No identifiable pattern of reactivity was found in 13 samples using gel testing compared with 6 for solid-phase and none for tube methodologies. Hemagglutination tube method was the best choice for our IRL because it missed the fewest number of clinically significant alloantibodies. Benefits also included the ability to use various potentiating factors, incubation times, and temperature phases to enhance antibody identification. The tube method provided critical data for determining antibody clinical significance. Immunohematology 2011;27:146–150.